Compass Therapeutics Investor Presentation Deck
Program Summary
>>>
>>>
»»>>
CTX-009 Novel DLL4 x VEGF-A bispecific antibody with both combination and monotherapy activity
Phase 1: Dose response established - responses in multiple indications
BTC Phase 2 results: 24 patients: 37.5% ORR (2L/3L), 63.6% (2L), median PFS 9.4 months, OS 12.5 months; initiating Phase 2/3
randomized study
CRC Phase 1 monotherapy activity in 3rd line: initiated Phase 2 in 4Q 2022
CTX-471 Potential best-in-class CD137 agonist antibody with monotherapy activity
Phase 1 monotherapy study fully enrolled
4 partial responses (PRs) in post PD-1 population: small cell lung cancer, metastatic melanoma, mucosal melanoma, mesothelioma
CTX-471 in combination with KEYTRUDA® study was initiated in 4Q 2022
CTX-8371 Next generation PD-1 x PD-L1 bispecific antibody
Discovered with our Stitch Mabs TM screening platform
Superior activity to commercial PD-1 and PD-L1 inhibitors in preclinical studies
Unique MOA - enhances T-cell activation
COMPASS
THERAPEUTICS
39View entire presentation